IDStewardship

DECEMBER 15, 2024

In this posta list of peculiar journal articles are highlighted, which may serve as conversationstarters from the medical literature. Authored by: Timothy P. Gauthier, Pharm.D., BCPS, BCIDP Social events like holiday parties or kids birthday parties can be unpredictable. Sometimes you know everyone and it is a lot of fun. Sometimes you do not know many people and you are stuck trying to make conversation with new acquaintances.

130

130

Med Ed 101

DECEMBER 15, 2024

Hypertension is one of the most common disease states that can lead to an increase in cardiovascular risk and other complications. Because of the risks of elevated blood pressure, we are often forced to use pharmacotherapy to reduce those risks. When a medication is started (or increased), we encounter risk in the form of adverse […] The post Hypertension Prescribing Cascade – 3 Common Examples appeared first on Med Ed 101.

52

52

Fierce Healthcare

DECEMBER 15, 2024

40

40

Pharmaceutical Technology

DECEMBER 15, 2024

Enlicitide decanoate is a peptide commercialized by Merck, with a leading Phase III program in Hypercholesterolemia.

40

40

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

The FDA Law Blog

DECEMBER 15, 2024

By Richard A. Lewis, Senior Regulatory Device & Biologics Expert & James E. Valentine We recently published the first part of our review of FDAs draft guidance titled Frequently Asked Questions Developing Potential Cellular and Gene Therapy Products. Questions and Answers Guidance (see previous coverage here ). In this post we focus in on the draft guidance documents chemistry, manufacturing, and controls (CMC)-specific content.

Documentation 52

Documentation FDA Immunization 52

Pharmaceutical Technology

DECEMBER 15, 2024

LY-3541860 is a monoclonal antibody commercialized by Eli Lilly and Co, with a leading Phase II program in Relapsing Multiple Sclerosis (RMS).

40

40

Pharmaceutical Technology

DECEMBER 15, 2024

Amycretin is a synthetic peptide commercialized by Novo Nordisk, with a leading Phase II program in Obesity.

40

40

Pharmaceutical Technology

DECEMBER 15, 2024

Eloralintide is a synthetic peptide commercialized by Eli Lilly and Co, with a leading Phase II program in Obesity.

40

40

Pharmaceutical Technology

DECEMBER 15, 2024

Sipavibart is a monoclonal antibody commercialized by AstraZeneca, with a leading Phase III program in Coronavirus Disease 2019 (COVID-19).

40

40

Pharmaceutical Technology

DECEMBER 15, 2024

RYZ-101 is a synthetic peptide commercialized by Bristol-Myers Squibb, with a leading Phase III program in Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET).

40

40

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Pharmaceutical Technology

DECEMBER 15, 2024

AZD-6234 is a synthetic peptide commercialized by AstraZeneca, with a leading Phase I program in Obesity.

40

40

Pharmaceutical Technology

DECEMBER 15, 2024

Ibuzatrelvir is a small molecule commercialized by Pfizer, with a leading Phase II program in Coronavirus Disease 2019 (COVID-19).

40

40

Pharmaceutical Technology

DECEMBER 15, 2024

NBI-1076986 is a small molecule commercialized by Neurocrine Biosciences, with a leading Phase I program in Movement Disorders.

40

40

Pharmaceutical Technology

DECEMBER 15, 2024

Descartes-08 is a gene-modified cell therapy commercialized by Cartesian Therapeutics, with a leading Phase II program in Myasthenia Gravis.

40

40

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Pharmaceutical Technology

DECEMBER 15, 2024

CTX-471 is a monoclonal antibody commercialized by Compass Pathways, with a leading Phase I program in Head And Neck Cancer.

40

40

Pharmaceutical Technology

DECEMBER 15, 2024

BMS-986446 is a monoclonal antibody commercialized by Bristol-Myers Squibb, with a leading Phase II program in Alzheimer's Disease.

40

40

Pharmaceutical Technology

DECEMBER 15, 2024

GSK-3858279 is a monoclonal antibody commercialized by GSK, with a leading Phase II program in Osteoarthritis Pain.

40

40

Pharmaceutical Technology

DECEMBER 15, 2024

(Dexborneol + Edaravone) is a small molecule commercialized by Simcere Pharmaceutical Group, with a leading Phase I program in Acute Ischemic Stroke.

40

40

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Pharmaceutical Technology

DECEMBER 15, 2024

Zipalertinib is a small molecule commercialized by Otsuka, with a leading Phase III program in Non-Small Cell Lung Cancer.

40

40

Pharmaceutical Technology

DECEMBER 15, 2024

Vanzacaftor + Deutivacaftor + Tezacaftor is a small molecule commercialized by Vertex Pharmaceuticals, with a leading Pre-Registration program in Cystic Fibrosis.

40

40

Pharmaceutical Technology

DECEMBER 15, 2024

GSK-3810109 is an antibody commercialized by GSK, with a leading Phase II program in Human Immunodeficiency Virus (HIV) Infections (AIDS).

40

40

Pharmaceutical Technology

DECEMBER 15, 2024

Vepdegestrant is a small molecule commercialized by Arvinas, with a leading Phase III program in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer).

40

40

Pharmaceutical Technology

DECEMBER 15, 2024

ATA-3219 is a gene-modified cell therapy commercialized by Atara Biotherapeutics, with a leading Phase I program in Diffuse Large B-Cell Lymphoma;Mantle Cell Lymphoma;Follicular Lymphoma;B-Cell Non-Hodgkin Lymphoma.

40

40